Long non-coding RNA RAB11B-AS1 prevents osteosarcoma development and progression via its natural antisense transcript RAB11B
Metrics: PDF 1518 views | HTML 1841 views | ?
Zhixu Chen1,*, Zezheng Liu1,*, Yang Yang1, Zhaoyin Zhu1, Ridong Liang1, Bin Huang1, Di Wu2, Lei Yang2, Hai Lu1, Dadi Jin1 and Qingchu Li1
1Academy of Orthopedics, Guangdong Province, Department of Orthopedics, The Third Affiliated Hospital, Southern Medical University, Guangzhou 510630, China
2The State Key Lab of Respiratory Disease, The Institute for Chemical Carcinogenesis, Collaborative Innovation Center for Environmental Toxicity, Guangzhou Medical University, Guangzhou 510182, China
*These authors contributed equally to this work
Qingchu Li, email: [email protected]
Keywords: lnc-RAB11B-AS1; osteosarcoma; RAB11B; proliferation; invasion
Received: January 25, 2017 Accepted: December 05, 2017 Epub: January 13, 2018 Published: June 01, 2018
Long non-coding RNAs (lncRNAs) have been shown to exert essential roles in development and progression of tumors. Here we discovered a novel lncRNA, RAB11B antisense RNA (RAB11B-AS1), which is markedly down-regulated in human osteosarcoma (OS) and associated with OS metastasis and poor prognosis. We find that reduction of RAB11B-AS1 significantly facilitates proliferation, migration and invasiveness and prevents apoptosis of OS cells and results in lower sensitivity to cisplatin in these cells. In contrast, up-regulation of RAB11B-AS1 suppresses the aggressive behaviors of OS cells. Mechanistically, down-regulation of RAB11B-AS1 elevates its sense-cognate gene RAB11B expression at both mRNA and protein levels. RAB11B-AS1 expression correlates negatively with RAB11B expression in OS tissues. Luciferase reporter assay illuminated that RAB11B-AS1 regulates RAB11B expression through antisense pairing. Most importantly, all the effects of RAB11B-AS1 were abrogated by RAB11B down-regulation. Thus our findings revealed that lnc-RAB11B-AS1 prevents osteosarcoma development and progression via inhibiting RAB11B expression, indicating lnc-RAB11B-AS1 as a potential therapeutic target for osteosarcoma.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.